Genetic test identifies breast cancer patients that can avoid chemotherapy and remain

[News]

Genomic Health has announced the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

More... (http://www.news-medical.net/news/20150928/Genetic-test-identifies-breast-cancer-patients-that-can-avoid-chemotherapy-and-remain-relapse-free-following-five-years-of-hormone-therapy.aspx)